Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of Los Angeles Times, shared a post on X:
“NCI-supported PRAGMATICA lung trial failed, but established real-world survival after chemo of 9 months. Our Bioshield trial in lung patients who progressed shows that when NK and T cells are activated, survival is doubled, and some patients live 4+ years in the late stage of cancer.
Coming this week.”
Adam Feuerstein, Senior Writer, National Biotech Columnist at STAT News, shared this post, adding:
“Dr. Soon-Shiong – Has $IBRX published the full data from the Quilt-3.055 NSCLC study? The presentations I’ve found are incomplete. Where can we find all the baseline data for study participants, for instance? That information is particularly relevant to better understand the claims you make about higher ALC leading to improved OS.”
Pat Soon-Shiong replied:
“Coming this week around the 9th.
Partial presentation at the World Lung Conference in Barcelona. Remainder in a publication being sent for Journal review. Conclusion: ALC matters! Increase in ALC with 1L15 superagonist translates to significant overall survival across lung cancer and 10 tumor types. The stats are amazing.”
More posts featuring Pat Soon-Shiong.